Daryl Dolynny

Thank you, Mr. Nadli. We’ll open up the floor to general comments. Question? Thank you. We’ll move to Ms. Bisaro.

I think the general public is a bit concerned here that this government, this department received one round of $2.5 million, just received a round of another $2.5 million, and we’re going to be breaking for the summer months, we’re not going to be back here in the House until October. Again, the question to ask: When can we see an expectation of information being shared to the public regarding the first round of due diligence studies of the so-called bore holes and how much aggregate or sand is out there? My second question: When can we see this new round of information be available to the...

Question is being called. The motion is carried.

---Carried

Does committee agree that consideration for Committee Report 3-17(3), Standing Committee on Government Operations Report on the Review of the Office of the NWT Languages Commissioner Annual Report 2010-2011, be concluded?

Thank you, Mr. Speaker. I don’t believe it was hypothetical. Anyone in construction or building has plans Bs and Cs just to make sure we have contingency plans. That said, I will be asking that question, I’m sure, later on in the Assembly.

Can the Minister be a bit more clairvoyant as to which date the government is proposing that this bridge be built and open for public? Hansards have a couple dates in there. We’ve seen the 24th. I’ve heard the 26th. Can the Minister be a bit more clear as to the AIP, this new agreement, which date is circled on the calendar for people to be excited about?

Back on February 16th of this calendar year, this side of the House passed a motion on the floor of the Legislative Assembly on anti-bullying. The sands of time are nearing the end in the hourglass and our question for the Minister of Education, Culture and Employment is: When will we get a response to that motion? Thank you.

Thank you. So what we’re hearing here is that there is a peer review process involved, that physicians are involved and it goes to Inuvik for further review. But can the Minister indicate to the House if there is an unfavourable response from this peer review, is there an appeals process that a patient or another health care provider can follow in order to get that drug covered? Thank you.

Thank you, Mr. Speaker. Today I have questions for the Minister of Health and it’s going to deal with pharmaceutical and prescription drugs, and I’ll be very easy on the Minister, Mr. Speaker.

The term “off-label use” is a term used in the industry where it means a drug has been discovered to have properties of use or therapeutic use for something that was outside of its intended use. In a lot of cases, drug companies don’t go to the case of actually making proof of claim because of costs. Drug benefits such as Blue Cross, extended health will look at this synopsis and make their decision...

Thank you, Mr. Speaker. Once in awhile a young man comes along who redefines human spirit and truly rewrites the scriptures on humanity and giving. Today I wish to inform the Members we have such a marvel who resides in the riding of Range Lake and his name is Mr. Cole Philipp.

It all started a couple of years ago when this student was in Grade 7 in Range Lake North School and he learned about “pay it forward,” which is a movement depicted in books, TV, mainstream and film. In essence, Mr. Speaker, this pay it forward program is a means to change the lives of others by doing good deeds for...

Thank you, Mr. Speaker. It’s very encouraging to hear that we are working towards an appeals program, but that could take several months, maybe years, to achieve. In the interim, can the Minister make a commitment to look, on a case-by-case basis, if it is brought to the department to look at those patients who are waiting in the wings patiently to hear from this government, so that they can get their drugs approved for their therapies that are not previously being covered by our programs?

Thank you. The Minister is correct; and non-insured health benefits are used as a means for formulary design. However, that system does have some gaping holes in the process and currently, right now, if a patient was to question viability of a drug being covered, it goes to Inuvik to extended benefits for review and it is reviewed, hopefully, by an independent source or a professional source. Does the Minister have information whether or not there is a process for a review that goes outside the formulary design of intention? Thank you.